Literature DB >> 34588793

Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation.

Ryan D Castle1, Michelle A Williams2, William C Bushell3, J Adam Rindfleisch4, Christine Tara Peterson5, James Marzolf6, Kimberly Brouwer7, Paul J Mills8.   

Abstract

INTRODUCTION: COVID-19 poses a chronic threat to inflammatory systems, reinforcing the need for efficient anti-inflammatory strategies. The purpose of this review and analysis was to determine the efficacy of various interventions upon the inflammatory markers most affected by COVID-19. The focus was on the markers associated with COVID-19, not the etiology of the virus itself.
METHODS: Based on 27 reviewed papers, information was extracted on the effects of COVID-19 upon inflammatory markers, then the effects of standard treatments (Remdesivir, Tocilizumab) and adjunctive interventions (vitamin D3, melatonin, and meditation) were extracted for those markers. These data were used to approximate effect sizes for the disease or interventions via standardized mean differences (SMD).
RESULTS: The data that were available indicated that adjunctive interventions affected 68.4% of the inflammatory markers impacted by COVID-19, while standard pharmaceutical medication affected 26.3%. DISCUSSION: Nonstandard adjunctive care appeared to have comparable or superior effects in comparison to Remdesivir and Tocilizumab on the inflammatory markers most impacted by COVID-19. Alongside standards of care, melatonin, vitamin D3, and meditation should be considered for treatment of SARS-COV-2 infection and COVID-19 disease.
© 2021 Castle et al.

Entities:  

Keywords:  COVID-19; antivirals; corticosteroids; cytokine storm; effect size; inflammation; meditation; melatonin; vitamin D; whole health

Year:  2021        PMID: 34588793      PMCID: PMC8473718          DOI: 10.2147/JIR.S323356

Source DB:  PubMed          Journal:  J Inflamm Res        ISSN: 1178-7031


  80 in total

1.  Interpreting estimates of treatment effects: implications for managed care.

Authors:  Stephen V Faraone
Journal:  P T       Date:  2008-12

2.  Long-COVID: An evolving problem with an extensive impact.

Authors:  M Mendelson; J Nel; L Blumberg; S A Madhi; M Dryden; W Stevens; F W D Venter
Journal:  S Afr Med J       Date:  2020-11-23

3.  [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].

Authors:  L Chen; H G Liu; W Liu; J Liu; K Liu; J Shang; Y Deng; S Wei
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2020-02-06

4.  [Mortality and re-admission after hospitalization with COVID-19].

Authors:  Wouter T Leijte; Nicolaas M M Wagemaker; Tom D A van Kraaij; Martijn D de Kruif; Guy J M Mostard; Math P G Leers; Rémy L M Mostard; Jacqueline Buijs; Daan J L van Twist
Journal:  Ned Tijdschr Geneeskd       Date:  2020-11-19

5.  The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis.

Authors:  H Cichoz-Lach; K Celinski; P C Konturek; S J Konturek; M Slomka
Journal:  J Physiol Pharmacol       Date:  2010-10       Impact factor: 3.011

6.  Clinical and immunological features of severe and moderate coronavirus disease 2019.

Authors:  Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 7.  The Global Epidemic of the Metabolic Syndrome.

Authors:  Mohammad G Saklayen
Journal:  Curr Hypertens Rep       Date:  2018-02-26       Impact factor: 5.369

8.  Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis.

Authors:  Awadhesh K Singh; Clare L Gillies; Ritu Singh; Akriti Singh; Yogini Chudasama; Briana Coles; Sam Seidu; Francesco Zaccardi; Melanie J Davies; Kamlesh Khunti
Journal:  Diabetes Obes Metab       Date:  2020-07-16       Impact factor: 6.408

9.  "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study".

Authors:  Marta Entrenas Castillo; Luis Manuel Entrenas Costa; José Manuel Vaquero Barrios; Juan Francisco Alcalá Díaz; José López Miranda; Roger Bouillon; José Manuel Quesada Gomez
Journal:  J Steroid Biochem Mol Biol       Date:  2020-08-29       Impact factor: 4.292

Review 10.  The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.

Authors:  Shalki Choudhary; Kajal Sharma; Om Silakari
Journal:  Microb Pathog       Date:  2020-12-02       Impact factor: 3.848

View more
  4 in total

Review 1.  A Peek into Pandora's Box: COVID-19 and Neurodegeneration.

Authors:  Abhishek Chandra; Ashu Johri
Journal:  Brain Sci       Date:  2022-01-30

Review 2.  Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.

Authors:  Russel J Reiter; Ramaswamy Sharma; Fedor Simko; Alberto Dominguez-Rodriguez; Jan Tesarik; Richard L Neel; Andrzej T Slominski; Konrad Kleszczynski; Verna M Martin-Gimenez; Walter Manucha; Daniel P Cardinali
Journal:  Cell Mol Life Sci       Date:  2022-02-20       Impact factor: 9.207

3.  Whole Person Health: The Role of Advocacy.

Authors:  Bill Reddy; Leonard A Wisneski
Journal:  Glob Adv Health Med       Date:  2022-03-09

Review 4.  The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-08-31       Impact factor: 3.766

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.